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What is the best way to distinguish 
type 1 and 2 diabetes?
■ Evidence summary
Onset of diabetes in childhood with
ketoacidosis and insulin dependency has
traditionally been sufficient to diagnose
type 1 diabetes, while onset in older, obese
patients with primary insulin resistance
suggested type 2 diabetes. Unfortunately,
features of type 1 and type 2 diabetes may
be present in the same patient, making dif-
ferentiation difficult. No diagnostic studies
in the literature were identified that defini-
tively demonstrate how to separate type 1
from type 2 diabetes.
A patient’s age may suggest, but does
not reliably distinguish, diabetes types. 
A study of 569 new-onset type 1 and type
2 diabetic children and adolescents showed
that older age was only weakly associated
with type 2 diagnosis (odds ratio [OR]=
1.4 for each 1-year increment in age; 95%
confidence interval [CI], 1.3–1.6).2 In fact,
newly diagnosed 12-year-old children have
an equal incidence of type 1 as type 2 dia-
betes. Likewise, adults with type 2 pheno-
type (no initial insulin requirement) can
present with positive autoantibodies typi-
cally found in younger type 1 patients.
Older patients who fit this profile have
Focus on attaining optimal diabetes control
goals as recommended by the ADA
Not long ago, clinicians were advised to avoid the
terms type 1 and type 2 diabetes, because they
were not very helpful in clinical management of
our patients. Instead, it was suggested that we use
insulin-dependent or non-insulin-dependent. The
rationale is that for patients with diabetes, there is
an absolute insulin deficiency due to premature
beta-cell failure in type 1 diabetes, as well as a rel-
ative insulin deficiency due to insulin resistance in
type 2. In addition, studies also suggest that a
majority of patients with type 2 diabetes would
require some form of exogenous insulin therapy
after a duration of 8 to 10 years of their disease.
Therefore, distinguishing between types 1 and 2 is
neither clinically helpful nor cost-effective, as 
suggested by current review of the literature.
Instead, clinicians should focus on attaining 
optimal diabetic control goals as recommended by
the practice guidelines of management of diabetes
mellitus from the ADA. Furthermore, it was also
recognized that one of the hurdles of failure to
reach the target goal of  HbA1C <7.0, among
patients with type 2 diabetes is the delayed use 
of exogenous insulin therapy. Therefore, it is
imperative for clinicians to discuss with each
patient with a new diagnosis of diabetes, the 
natural progression of its disease process and its
potential need and benefit of exogenous insulin
therapy in the near future.
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No clinical characteristic or diagnostic test is 
available to readily distinguish type 1 from type 2
diabetes mellitus. Although C-peptide levels,
autoantibodies, and adiponectin-to-leptin ratios
show some utility, they do not yet have a standard
diagnostic role; research on the pathophysiology
of diabetes suggests that the classic type 1 and
type 2 distinctions may not be appropriate for all
patients1 (strength of recommendation: C, based
on expert opinion).
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been classified as type 1.5 diabetes or latent
autoimmune disease in adults (LADA).3
A history of diabetic ketoacidosis
(DKA) also does not reliably distinguish
between types 1 and 2. A retrospective chart
review gathered data on adults over 18
years of age who were admitted for DKA in
a urban US hospital. Many patients with
DKA were subsequently diagnosed with
type 2 diabetes. Rates of type 2 diabetes in
patients with DKA varied by race: 47% of
Hispanics, 44% of African Americans, and
17% of Caucasians had type 2 diabetes.4
The overlapping presence of autoanti-
bodies in both types of diabetes limits their
use (TABLE). Autoantibodies do predict an
earlier need for insulin. One prevalence
study of 101 type 2 adult patients found
20% were positive for glutamic acid decar-
boxylase autoantibody (GADAb), which
was positively associated with insulin
dependence at 4 years postdiagnosis
(OR=5.8; 95% CI, 1.8–18.9).5 Eighty per-
cent of patients with autoantibodies required
insulin compared with 41% of patients
without autoantibodies. Another study in
young adults with type 2 or unclassified dia-
betes from Sweden found 93% of patients
who were GADAb+ required insulin at 3
years, compared with 51% who were
GADAb– (OR=18.8; 95% CI, 1.8–191).6
One motivation to study autoantibody
testing is a potential benefit in preserving
pancreatic function. Kobayashi proposed
treating those with autoantibody-positive
diabetes (presumed type 1 or type 1.5)
with insulin immediately, while initiating
oral medications in those who test negative
(presumed type 2 diabetes). This approach
lacks significant patient-oriented outcome
data, but his small RCT of 55 patients was
encouraging. With a 3-year follow-up rate
of 89%, early insulin use in GADAb+
patients preserved C-peptide levels and
possibly prolonged pancreatic beta cell
survival.7 Insulin dependency, defined as
needing insulin for survival, occurred in
47% of controls (who received oral sul-
fonylureas) and only 13% of patients
receiving insulin (number needed to treat
[NNT]= 4; P=.043).7 The theoretical bene-
fit is that if beta cell exhaustion can be
delayed, endogenous insulin production
could be maintained to assist prevention of
damaging postprandial glucose spikes. 
Although daily variation in serum
insulin levels limits its use, C-peptide levels
show more promise. Random C-peptide
levels were superior to fasting or glucagon
stimulated levels in 1093 patients, who
were followed for 3 years to confirm
insulin requirements. Using a receiver
operating characteristic (ROC) curve, the
area under the curve for random C-peptide
levels to distinguish diabetes types was
0.98 (95% CI, 0.97–0.99).8 For patients
under the optimal cutoff of 0.5 nmol/L, the
positive predictive value was 96% for
diagnosing type 1 and the likelihood ratio
was 22.5. 
Finally, the ratio of adiponectin to lep-
tin hormone may show diagnostic merit.
Adipocytes secrete adiponectin which acts
as an insulin sensitizer, antiatherogenic and
anti-inflammatory agent. Obesity and type
2 phenotype correlate with lower levels of
adiponectin, but are associated with higher
levels of leptin hormone, another molecule
secreted by adipocytes. A recent case-con-
trol study of children aged 6 to 21 years
analyzed adiponectin and leptin hormone
levels in patients with classical type 1 and 2
diabetes, as determined by 2 pediatric
endocrinologists; interestingly, 29% of the
type 1 patients were autoantibody nega-
tive.9 After plotting a ROC curve, they
found the area under the curve was 0.97
(95% CI, 0.93–1.00). At an adiponectin-
to-leptin ratio cutoff less than 0.7, they
The classic type 1
and type 2 
distinctions may
not be appropriate
for all patients
FAST TRACK
T A B L E 1
PREVALENCE OF ANY AUTOANTIBODY MARKER PERCENT
Newly diagnosed type 1 (Caucasian) 73–90
Newly diagnosed type 1 (African or Asian) 50
Newly diagnosed type 2 (Caucasian) 3–22
Healthy individuals 1–2
Source: Wingfield et al 20041 and Maron et al 1996.3
Antibody markers and diabetes type
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found the sensitivity to diagnose type 2 was
88% (95% CI, 64–99%), the specificity
was 90% (95% CI, 77–97), and the likeli-
hood ratio for a positive test was 8.8.9
Recommendations from others
The National Academy of Clinical
Biochemistry and the American Association
of Clinical Endocrinologists recommend
against routine testing of insulin, C-peptide,
autoantibodies and genetic markers.1,10
Guidelines from the American Diabetes
Association admit that many diabetic indi-
viduals do not easily fit into a distinct diag-
nostic category; however, they only provide
criteria for the general diagnosis of diabetes,
not specific criteria to distinguish type 1
from type 2.11
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Sports Medicine, American Medical Society
for Sports Medicine, American Orthopedic
Society for Sports Medicine, and the
American Osteopathic Academy of Sports
Medicine, published recommendations for
PPEs. They suggested a detailed history
(consisting of a 16-point questionnaire
incorporating AHA recommendations for
cardiovascular screening), limited medical
exam, and a detailed musculoskeletal exam
evaluating strength, flexibility, and stability
of major joints.7
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